youtube_live
Q3 2026 earnings • in 4 days
See detailschevron_right
BBIO:NASDAQ
BridgeBio Pharma Inc
$68.56
arrow_upward
+0.65%(+0.44) 1D
$68.56
0.00% (0.00)
bedtimeAfter hours
Closed: Oct 23, 4:00:01 PM GMT-4 · USD
search
All symbols
No data
| Symbol | Price | Change | % Change |
|---|
insights_autoGenerating top insights for BBIO...
Open
$67.69
High
$68.86
Low
$67.02
Mkt. cap
13.40B
Avg. vol.
2.91M
Volume
2.40M
52-wk high
$93.42
52-wk low
$54.23
EPS
-$3.57
Beta
0.97
Shares outstanding
195.49M
No. of employees
1K
Open
$67.69
High
$68.86
Low
$67.02
Mkt. cap
13.40B
Avg. vol.
2.91M
Volume
2.40M
52-wk high
$93.42
52-wk low
$54.23
EPS
-$3.57
Beta
0.97
Shares outstanding
195.49M
No. of employees
1K
News stories
From web sources and news partners
Yahoo Finance
·
3 hours ago
Zero-Day Option Traders Are Betting Against Big S&P 500 Swings
Benzinga
·
1 hour ago
S&P 500, VOO, and SPY Outlook: What Investors Need to Watch This Week
Yahoo Finance
·
1 hour ago
Up 35%, How Long Can Coca-Cola Continue Crushing the S&P 500?
About BridgeBio Pharma Inc
CEONeil Kumar
Employees1K
Founded2015
HeadquartersPalo Alto, California, United States
SectorBiotechnology
Websitebridgebio.com
Analyst ratings
Based on 18 analysts giving stock ratings to BBIO in the past 3 months
Strong buy
Buy
17
Hold
1
Sell
0
12-month forecast
Based on 18 Wall Street analysts offering 12 month price targets for BBIO in the last 3 months.
Highest
Current $68.56
$156.00 (+127.54%)
Average
$109.65 (+59.93%)
Lowest
$87.00 (+26.90%)
Analyst | Recommendation | Action | Price target | Projected | Date |
|---|---|---|---|---|---|
Sean Laaman Morgan Stanley | Buy | Maintained | $87.00 | +26.9% | 10/22/2026 |
Biren Amin Piper Sandler | Buy | Maintained | $120.00 | +75% | 10/19/2026 |
Jason Zemansky Bank of America Securities | Buy | Reiterated | $102.00 | +48.8% | 10/19/2026 |
Eric Joseph Citi | Hold | Maintained | $91.00 | +32.7% | 10/20/2026 |
Yanan Zhu Wells Fargo | Buy | Maintained | $102.00 | +48.8% | 10/15/2026 |
Joon Lee UBS | Buy | Initiated | $92.00 | +34.2% | 10/16/2026 |
Ram Selvaraju H.C. Wainwright | Buy | Reiterated | $120.00 | +75% | 10/15/2026 |
Luca Issi RBC Capital | Buy | Maintained | $100.00 | +45.9% | 10/08/2026 |
Whitney Ijem Canaccord Genuity | Buy | Maintained | $106.00 | +54.6% | 10/06/2026 |
Eliana Merle Barclays | Buy | Maintained | $156.00 | +127.5% | 10/07/2026 |
Myles Minter William Blair | Buy | Reiterated | - | - | 10/06/2026 |
Tyler Van Buren TD Cowen | Buy | Reiterated | $110.00 | +60.4% | 09/24/2026 |
Cory Kasimov Evercore ISI | Buy | Maintained | $130.00 | +89.6% | 09/14/2026 |
Salim Syed Mizuho Securities | Buy | Maintained | $110.00 | +60.4% | 08/31/2026 |
Andrew Tsai Jefferies | Buy | Maintained | $110.00 | +60.4% | 08/31/2026 |
Joshua Schimmer Cantor Fitzgerald | Buy | Maintained | $110.00 | +60.4% | 08/29/2026 |
Anupam Rama J.P. Morgan | Buy | Reiterated | $111.00 | +61.9% | 08/12/2026 |
Danielle Brill Truist Financial | Buy | Maintained | $107.00 | +56.1% | 08/12/2026 |
Derek Archila Wells Fargo | Buy | Reiterated | $102.00 | +48.8% | 08/11/2026 |
Unknown Analyst Wells Fargo | Buy | Reiterated | $102.00 | +48.8% | 08/11/2026 |
Tiago Fauth Raymond James | Buy | Maintained | $98.00 | +42.9% | 06/17/2026 |
Martin Auster Raymond James | Hold | Downgraded | - | - | 05/26/2026 |
Unknown Analyst Citi | Hold | Initiated | - | - | 05/19/2026 |
William Pickering Bernstein | Buy | Reiterated | $114.00 | +66.3% | 05/08/2026 |
Paul Choi Goldman Sachs | Buy | Maintained | $116.00 | +69.2% | 05/08/2026 |
Matt Phipps William Blair | Buy | Reiterated | - | - | 05/02/2026 |
Lisa Walter RBC Capital | Buy | Initiated | $100.00 | +45.9% | 04/08/2026 |
Trevor Allred Oppenheimer | Buy | Maintained | $81.00 | +18.1% | 02/25/2026 |
Next call in 4 days
Thu, Oct 29, 4:30 PM
Fiscal period
Q3 2026
- Normalized EPS / Est. (USD)
- GAAP EPS / Est. (USD)
- / -$0.56
Revenue / Est. (USD)
- / 295.75M
Fiscal Q3 2026 earnings call
youtube_liveWaiting for the earnings call
At a glance: upcoming earnings
Insights from the latest news and reports
Previous reportsAll values in USD
Loading Previous Earnings...
Income statement
Revenue
Net income
- Quarterly
- Annual
All values in USD | Sep 2025 | Dec 2025 | Mar 2026 | Jun 2026 |
|---|---|---|---|---|
Revenue | 120.70M | 154.18M | 194.52M | 243.68M |
Cost of goods sold | 6.56M | 8.11M | 9.94M | 15.05M |
Cost of revenue | 6.56M | 8.11M | 9.94M | 15.05M |
Research and development expenses | 112.87M | 116.42M | 126.64M | 149.45M |
Total research and development expenses | - | - | - | - |
Selling, general, and admin expenses | 137.62M | 158.08M | 163.90M | 186.26M |
Operating expense | 250.50M | 274.50M | 290.53M | 335.71M |
Total operating expenses | 257.06M | 282.61M | 300.47M | 350.76M |
Operating income | -136.36M | -128.43M | -105.96M | -107.08M |
Other non operating income | 16.46M | 11.82M | 4.25M | 5.59M |
EBT including unusual items | -186.48M | -194.76M | -166.56M | -155.89M |
EBT excluding unusual items | -177.64M | -183.62M | -166.56M | -155.89M |
Income tax expense | -1.54M | -120.00K | - | - |
Effective tax rate | 0.83% | 0.06% | - | - |
Other operating expenses | - | - | - | - |
Net income | -182.74M | -192.86M | -164.04M | -152.22M |
Net profit margin | -151.40% | -125.09% | -84.33% | -62.47% |
Earnings per share | -0.72 | -0.94 | -0.84 | -0.78 |
Interest and investment income | 6.24M | 4.33M | 6.25M | 6.66M |
Interest expense | -48.15M | -50.31M | -52.82M | -54.62M |
Net interest expenses | -41.91M | -45.98M | -46.57M | -47.96M |
Depreciation and amortization charges | - | - | - | - |
EBITDA | -134.96M | -127.00M | -104.77M | -106.03M |
Gain or loss from assets sale | - | - | - | - |
Insider transactions
Insider transactions data is drawn from third-party sources. Learn more
Insider | Position | Type | Date | Shares | Amount |
|---|---|---|---|---|---|
Page 1